| 1 |
Paik PK, Pillai RN, Lathan CS, et al. New treatment options in advanced squamous cell lung cancer[J]. Am Soc Clin Oncol Educ Book, 2019, 39: e198-e206.
|
| 2 |
王洪武，金发光. 晚期非小细胞肺癌多域整合治疗策略[J/CD]. 中华肺部疾病杂志(电子版), 2022, 15(4): 457-461.
|
| 3 |
Cheung AH, Tong JH, Chung LY, et al. EGFR mutation exists in squamous cell lung carcinoma[J]. Pathology, 2020, 52(3): 323-328.
|
| 4 |
Wang H, Sun L, Sang Y, et al. A study of ALK-positive pulmonary squamous-cell carcinoma: From diagnostic methodologies to clinical efficacy[J]. Lung Cancer, 2019, 130: 135-142.
|
| 5 |
Evison M, AstraZeneca UK Limited. The current treatment landscape in the UK for stage Ⅲ NSCLC[J]. Br J Cancer, 2020, 123(Suppl 1): 3-9.
|
| 6 |
Curioni-Fontecedro A, Perentes JY, Gelpke H, et al. Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage ⅢB NSCLC: a multicentre phase 2 trial (SAKK 16/08) [J]. Br J Cancer, 2019, 120(10): 968-974.
|
| 7 |
Wolf M. Adjuvant and inductive systemic treatment in non-small cell lung cancer[J]. Chirurg, 2019, 90(12): 982-990.
|
| 8 |
Bryan DS, Donington JS. The role of surgery in management of locally advanced non-small cell lung cancer[J]. Curr Treat Options Oncol, 2019, 20(4): 27.
|
| 9 |
Palmero R, Vilariño N, Navarro-Martín A, et al. Induction treatment in patients with stage Ⅲ non-small cell lung cancer[J]. Transl Lung Cancer Res, 2021, 10(1): 539-554.
|
| 10 |
Ren S, Chen J, Xu X, et al. Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-Sq): A phase 3 trial[J]. J Thorac Oncol, 2022, 17(4): 544-557.
|
| 11 |
Simon GR. Nab-Paclitaxel for the treatment of advanced squamous non-small-cell lung cancer: a comprehensive update[J]. Clin Lung Cancer, 2014, 15(6): 391-397.
|
| 12 |
Villaruz LC, Cobo M, Syrigos K, et al. A phase Ⅱ study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage Ⅳ squamous non-small cell lung cancer[J]. Lung Cancer, 2019, 136: 52-56.
|
| 13 |
Zajczkowska R, Kocot-Kpska M, Leppert W, et al. Mechanisms of chemotherapy-induced peripheral neuropathy[J]. Int J Mol Sci, 2019, 20(6): 1451.
|
| 14 |
Klein I, Lehmann HC. Pathomechanisms of paclitaxel-induced peripheral neuropathy[J]. Toxics, 2021, 9(10): 229.
|
| 15 |
Tofthagen CS, Cheville AL, Loprinzi CL. The physical consequences of chemotherapy-induced peripheral neuropathy[J]. Curr Oncol Re, 2020, 22(5): 50.
|
| 16 |
Bland KA, Kirkham AA, Bovard J, et al. Effect of exercise on taxane chemotherapy-induced peripheral neuropathy in women with breast cancer: A randomized controlled trial[J]. Clin Breast Cancer, 2019, 19(6): 411-422.
|
| 17 |
Gu J, Lu H, Chen C, et al. Diabetes mellitus as a risk factor for chemotherapy-induced peripheral neuropathy: a meta-analysis[J]. Support Care Cancer, 2021, 29(12): 7461-7469.
|
| 18 |
Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors[J]. Nat Rev Dis Primers, 2020, 6(1): 38.
|
| 19 |
Quandt Z, Young A, Anderson M. Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes[J]. Clin Exp Immunol, 2020, 200(2): 131-140.
|
| 20 |
Fife BT, Pauken KE, Eagar TN, et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal[J]. Nat Immunol, 2009, 10(11): 1185-1192.
|
| 21 |
Qian C, Guo H, Chen X, et al. Association of PD-1 and PD-L1 genetic polymorphyisms with type 1 diabetes susceptibility[J]. J Diabetes Res, 2018, 2018: 1614683.
|
| 22 |
Akturk HK, Kahramangil D, Sarwal A, et al. Immune checkpoint inhibitor-induced Type 1 diabetes: a systematic review and meta-analysis[J]. Diabet Med, 2019, 36(9): 1075-1081.
|
| 23 |
Byun DJ, Braunstein R, Flynn J, et al. Immune checkpoint inhibitor-associated diabetes: A single-institution experience[J]. Diabetes Care, 2020, 43(12): 3106-3109.
|
| 24 |
Fang W, Yang Y, Ma Y, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials[J]. Lancet Oncol, 2018, 19(10): 1338-1350.
|
| 25 |
续广娟，周 琴，陈 喆. 注射用卡瑞利珠单抗致糖尿病酮症酸中毒合并血小板减少1例[J]. 中国药师，2021, 24(3): 531-534.
|